- X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference
- X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million